# reload+after+2024-01-22 21:48:05.110101
address1§3710 – 33rd Street NW
city§Alberta Beach
state§AB
zip§T2L 2M1
country§Canada
phone§403 455 7727
website§https://www.xortx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.
fullTimeEmployees§3
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Allen Warren Davidoff Ph.D.', 'age': 63, 'title': 'Founder, CEO, President & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 366603, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James Neville Fairbairn C.A., C.P.A., ICD.D', 'age': 60, 'title': 'Interim Chief Financial Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 43735, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stephen  Haworth M.D., MRCP', 'age': 73, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 233562, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Stacy  Evans M.B.A., M.D.', 'age': 49, 'title': 'Chief Business Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 86456, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Nick  Rigopoulos', 'title': 'Director of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Sans M.B.A., Ph.D.', 'age': 54, 'title': 'Director of Corporate Development', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  MacDonald Ph.D.', 'age': 59, 'title': 'Consultant of Clinical Operations', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Charlotte  May', 'title': 'Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.095
currency§USD
dateShortInterest§1702598400
forwardEps§-1.72
exchange§NCM
quoteType§EQUITY
shortName§XORTX Therapeutics Inc.
longName§XORTX Therapeutics Inc.
firstTradeDateEpochUtc§1632403800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ccf511eb-7240-3e07-af90-4d0cc6586c46
gmtOffSetMilliseconds§-18000000
targetHighPrice§29.65
targetLowPrice§13.97
targetMeanPrice§21.82
targetMedianPrice§21.82
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§9.277
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
